Neurocrine Biosciences, Inc (NASDAQ: NBIX) kicked off on Tuesday, down -0.36% from the previous trading day, before settling in for the closing price of $125.89. Over the past 52 weeks, NBIX has traded in a range of $110.95-$157.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 34.77%. While this was happening, its average annual earnings per share was recorded 72.87%. With a float of $98.53 million, this company’s outstanding shares have now reached $101.20 million.
The extent of productivity of a business whose workforce counts for 1400 workers is very important to gauge. In terms of profitability, gross margin is 98.0%, operating margin of 26.19%, and the pretax margin is 23.26%.
Neurocrine Biosciences, Inc (NBIX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Neurocrine Biosciences, Inc is 2.68%, while institutional ownership is 91.89%. The most recent insider transaction that took place on Nov 29 ’24, was worth 294,373. In this transaction Chief Scientific Officer of this company sold 2,331 shares at a rate of $126.29, taking the stock ownership to the 15,449 shares. Before that another transaction happened on Nov 29 ’24, when Company’s Officer proposed sale 2,331 for $126.59, making the entire transaction worth $295,081.
Neurocrine Biosciences, Inc (NBIX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 72.87% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 59.00% during the next five years compared to 62.04% growth over the previous five years of trading.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Trading Performance Indicators
Take a look at Neurocrine Biosciences, Inc’s (NBIX) current performance indicators. Last quarter, stock had a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.66. Likewise, its price to free cash flow for the trailing twelve months is 28.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.73, a number that is poised to hit 1.61 in the next quarter and is forecasted to reach 6.45 in one year’s time.
Technical Analysis of Neurocrine Biosciences, Inc (NBIX)
The latest stats from [Neurocrine Biosciences, Inc, NBIX] show that its last 5-days average volume of 0.69 million was inferior to 0.87 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 79.92%. Additionally, its Average True Range was 3.09.
During the past 100 days, Neurocrine Biosciences, Inc’s (NBIX) raw stochastic average was set at 30.81%, which indicates a significant decrease from 78.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.54% in the past 14 days, which was lower than the 43.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $119.40, while its 200-day Moving Average is $133.19. Now, the first resistance to watch is $126.53. This is followed by the second major resistance level at $127.61. The third major resistance level sits at $128.25. If the price goes on to break the first support level at $124.81, it is likely to go to the next support level at $124.17. Assuming the price breaks the second support level, the third support level stands at $123.09.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Key Stats
The company with the Market Capitalisation of 12.70 billion has total of 101,247K Shares Outstanding. Its annual sales at the moment are 1,887 M in contrast with the sum of 249,700 K annual income. Company’s last quarter sales were recorded 622,100 K and last quarter income was 129,800 K.
